The BSRBR Ankylosing Spondylitis Register



The BSR Biologics Register for patients with ankylosing spondylitis launched in April 2012. Registration opened in October 2012 and is currently recruiting patients.

The register monitors the long-term safety of these treatments and increase our understanding of their effects. This will include studying their efficacy, cost-efficacy, toxicity, adherence to guidance, and information on the effects of discontinuation of treatment or switching agents.

The register recruits patients with ankylosing spondylitis who are being prescribed adalimumab, etanercept or certolizumab pegol as well as a control group of patients who have not been prescribed biologics.

The BSRBR-AS register is managed for the BSR by Professor Gary Macfarlane and Dr Gareth Jones of the Epidemiology Group at the University of Aberdeen, who supervise the data collection and analysis.

For more information and contact details, please visit the contacts page. Alternativelly, please contact Ali Rivett, arivett@rheumatology.org.uk or Alan Roach, aroach@rheumatology.org.uk.